Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 9/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8917088 | 0.87 | KCNH2 (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2611058 | 0.87 | CA9 (0.57) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL29754329 | 0.87 | CA9 (0.57) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL29337400 | 0.84 | CA9 (0.58) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL4259653 | 0.83 | CA9 (0.50) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL1890344 | 0.83 | CA9 (0.50) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL1880793 | 0.82 | CA9 (0.53) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL1880791 | 0.82 | CA9 (0.53) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL1885817 | 0.80 | CA9 (0.50) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL18500484 | 0.79 | CA9 (0.53) | CA9NPC1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239159-B | 7-piperidinoalkyl-3,4-dihydroquinolone derivative | TAISHO PHARMACEUTICAL CO LTD | 2014-06-25 | — | — | CN | disclosed |
| EP-2344471-B1 | 7-PIPERIDINOALKYL-3,4-DIHYDROQUINOLONE DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8461182-B2 | 7-piperidinoalkyl-3, 4-Dihydroquinolone derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110178304-A1 | 7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178304-A1 | 7-PIPERIDINOALKYL-3, 4-DIHYDROQUINOLONE DERIVATIVE | MCHR1, MCHR2, GPR119 | CA9 4726/4885NPC1 355/4885MAPK13 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.